These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12052630)

  • 1. Use of surrogate antimicrobial agents to predict susceptibility to ertapenem.
    Friedland IR; Isaacs R; Mixson LA; Motyl M; Woods GL
    Diagn Microbiol Infect Dis; 2002 May; 43(1):61-4. PubMed ID: 12052630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
    Yamaguchi K; Mathai D; Biedenbach DJ; Lewis MT; Gales AC; Jones RN
    Diagn Microbiol Infect Dis; 1999 Jun; 34(2):123-34. PubMed ID: 10354863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme.
    Reynolds R; Potz N; Colman M; Williams A; Livermore D; MacGowan A;
    J Antimicrob Chemother; 2004 Jun; 53(6):1018-32. PubMed ID: 15128723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Activity of ertapenem and 19 other antimicrobial agents against beta-lactam-resistant Streptococcus pneumoniae and Haemophilus influenzae respiratory tract isolates].
    Gómez-Garcés JL; Alós JI; Alhambra A; Hernáiz C
    Enferm Infecc Microbiol Clin; 2005 Feb; 23(2):67-70. PubMed ID: 15743576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [In vitro activity of ertapenem against clinical bacterial isolates in 69 Spanish medical centers (E-test study)].
    Gobernado M; Sanz-Rodríguez C; Villanueva R; Torroba L; Redondo E; González-Esteban J
    Rev Esp Quimioter; 2007 Dec; 20(4):395-408. PubMed ID: 18563213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of antimicrobial susceptibility for beta-lactams using the Etest method against clinical isolates from 100 medical centers in Japan (2006).
    Ishii Y; Tateda K; Yamaguchi K;
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):177-83. PubMed ID: 17931820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia.
    Livermore DM; Carter MW; Bagel S; Wiedemann B; Baquero F; Loza E; Endtz HP; van Den Braak N; Fernandes CJ; Fernandes L; Frimodt-Moller N; Rasmussen LS; Giamarellou H; Giamarellos-Bourboulis E; Jarlier V; Nguyen J; Nord CE; Struelens MJ; Nonhoff C; Turnidge J; Bell J; Zbinden R; Pfister S; Mixson L; Shungu DL
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1860-7. PubMed ID: 11353638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of ertapenem: review of recent studies.
    Wexler HM
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of the in vitro spectrum of activity of imipenem.
    Jones RN
    Am J Med; 1985 Jun; 78(6A):22-32. PubMed ID: 3890537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative in vitro activity of ertapenem against aerobic and anaerobic bacteria].
    Loza E; Morosini MI; Cantón R; Almaraz F; Reig M; Baquero F
    Rev Esp Quimioter; 2003 Jun; 16(2):209-15. PubMed ID: 12973459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
    Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
    J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan.
    Lee SC; Huang SS; Lee CW; Fung CP; Lee N; Shieh WB; Siu LK
    BMC Infect Dis; 2007 Jul; 7():79. PubMed ID: 17640342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro activity of ertapenem against bacterial pathogens isolated from patients with lower respiratory tract infections.
    Hicks PS; Pelak B; Woods GL; Bartizal KF; Motyl M
    Clin Microbiol Infect; 2002 Nov; 8(11):753-7. PubMed ID: 12445016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of bacterial resistance to imipenem and ciprofloxacin in a university hospital.
    Fass RJ; Barnishan J; Ayers LW
    J Antimicrob Chemother; 1995 Aug; 36(2):343-53. PubMed ID: 8522464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation prevention concentration of ceftriaxone, meropenem, imipenem, and ertapenem against three strains of Streptococcus pneumoniae.
    Hovde LB; Rotschafer SE; Ibrahim KH; Gunderson B; Hermsen ED; Rotschafer JC
    Diagn Microbiol Infect Dis; 2003 Apr; 45(4):265-7. PubMed ID: 12729997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR; Frei CR; Burgess DS
    Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
    Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
    Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bactericidal activity and killing rate of serum against gram-positive cocci in volunteers receiving imipenem, oxacillin, vancomycin or ampicillin plus gentamicin.
    Van der Auwera P; Van Laethem Y; Klastersky J
    J Antimicrob Chemother; 1987 Aug; 20(2):239-49. PubMed ID: 3478329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.